Calcipotriol plus betamethasone ointment improves symptoms of nail psoriasis, researchers say.
(4/3, McDermid) reports that, according to a
published online in the journal Dermatology, "a two-compound ointment containing calcipotriol and betamethasone improves the symptoms of patients with nail psoriasis." For the study, researchers from the University of Athens Medical School in Greece "recruited 22 psoriasis patients with mild dermatological symptoms and 114 involved nails," then "treated them with a two-compound calcipotriol plus betamethasone ointment for 12 weeks." Participants "were instructed to apply the ointment at bedtime and to avoid washing their hands until the next morning." The investigators said that "this treatment regimen resulted in a 72 percent reduction in average Nail Psoriasis Severity Index (NAPSI) scores -- from 5.8 at baseline to 1.6 at 12 weeks." In particular, "the ointment was most effective for reducing hyperkeratosis...and onycholysis," and "also caused moderate improvements in oil drops and slight improvements in pitting."
Study indicates calcipotriol, betamethasone dipropionate ointment may be more effective for treatment of scalp psoriasis.
(4/3, Piper) reports that, according to a
published online in the British Journal of Dermatology, a "once-daily combination" regimen of "calcipotriol plus betamethasone dipropionate" appears to be "significantly more effective and better tolerated than twice-daily calcipotriol scalp solution alone for the treatment of scalp psoriasis." For the study, researchers from Denmark's Aarhus University Hospital compared the combination formulation's "clinical efficacy and safety" against "twice-daily calcipotriol, for scalp psoriasis," and found that "significantly more of the 207 patients receiving the two-compound solution reported relief from itching and were 'clear' of psoriasis or had 'minimal disease' after eight weeks of treatment than the 105 receiving calcipotriol, at 68.6...versus 31.4 percent." Moreover, "improvement was rapid with a significant difference evident as early as week two." The authors noted, however, "that maintenance therapy with the two-compound scalp formulation may be necessary after observing a relapse rate of 54.1 percent."
No comments:
Post a Comment